Compare DTM & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DTM | HALO |
|---|---|---|
| Founded | 2021 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 12.0B |
| IPO Year | 2021 | 2001 |
| Metric | DTM | HALO |
|---|---|---|
| Price | $123.13 | $116.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 9 |
| Target Price | ★ $151.33 | $104.89 |
| AVG Volume (30 Days) | 811.1K | ★ 2.4M |
| Earning Date | 10-29-2026 | 11-02-2026 |
| Dividend Yield | ★ 2.78% | N/A |
| EPS Growth | ★ 19.44 | N/A |
| EPS | 2.36 | ★ 3.11 |
| Revenue | ★ $1,243,000,000.00 | $151,862,000.00 |
| Revenue This Year | $9.40 | $34.87 |
| Revenue Next Year | $4.03 | $10.94 |
| P/E Ratio | $53.62 | ★ $35.25 |
| Revenue Growth | ★ 26.71 | N/A |
| 52 Week Low | $104.99 | $61.23 |
| 52 Week High | $152.88 | $116.85 |
| Indicator | DTM | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 43.84 | 64.26 |
| Support Level | $116.98 | $105.27 |
| Resistance Level | $150.07 | N/A |
| Average True Range (ATR) | 2.54 | 3.28 |
| MACD | 0.65 | -0.10 |
| Stochastic Oscillator | 54.92 | 81.49 |
DT Midstream Inc is an owner, operator, and developer of natural gas midstream interstate and intrastate pipelines; storage and gathering systems; and compression, treatment, and surface facilities. It provides multiple, integrated natural gas services to customers through interstate pipelines, intrastate pipelines, storage systems, lateral pipelines and related treatment plants and compression and surface facilities, and gathering systems and related treatment plants and compression and surface facilities. The segments of the group are Pipeline and Gathering. It generates maximum revenue from pipeline segment that includes interstate pipelines, storage systems, gathering lateral pipelines and compression and surface facilities.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.